| Similar Articles |
|---|
 |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting.   |
The Motley Fool
August 15, 2011
Brian Orelli |
Another Partner, but Still No Data Sequenom signs up a European partner. |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
The Motley Fool
October 18, 2011
Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool
September 24, 2008
Brian Orelli |
100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in. |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
September 18, 2009
Brian Orelli |
Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom. |
The Motley Fool
June 27, 2008
Brian Orelli |
The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
The Motley Fool
February 18, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week?: Seagate Technology... Prospect Capital... Interactive Intelligence... Sequenom... 99 Cents Only Stores... |
The Motley Fool
January 30, 2009
Brian Orelli |
Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics. |
The Motley Fool
November 30, 2010
Brian Orelli |
Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers. |
The Motley Fool
December 20, 2011
Brian Orelli |
What's Up With the Back-Slapping, Sequenom? Some sales numbers would be nice. |
The Motley Fool
October 25, 2007
Brian Orelli |
Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter. |
The Motley Fool
March 16, 2010
Brian Orelli |
No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move |
The Motley Fool
June 10, 2009
Brian Orelli |
Up 58% on No News? What's Going On? There's no concrete reason for the massive increase in Sequenom yesterday. The stock was flat until noon, then it steadily climbed up to the moon in afternoon trading. |
The Motley Fool
December 22, 2009
Brian Orelli |
2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes." |
The Motley Fool
October 6, 2010
Jeremy Phillips |
Reasons to Sell Sequenom Today Over the past 12 months, Sequenom has risen 115.7% versus an S&P 500 return of 11.3%. Investors in Sequenom have every reason to be proud of their returns. |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more? |
The Motley Fool
September 30, 2009
Brian Orelli |
Call Me a Wimp, but I'm Still Nervous Can the mud Sequenom seems to be running in turn to quicksand? |
The Motley Fool
June 3, 2010
Brian Orelli |
The Dragon That Cost Investors Millions The Securities and Exchange Commission filed a complaint against Elizabeth Dragon, the company's former Senior Vice President of Research and Development. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
August 16, 2011
Jeremy Phillips |
Read This Before You Think About Selling Sequenom I consider a debt-to-equity ratio below 50% to be healthy, though the number varies by industry. Sequenom is currently below this level, at 1.1%. |
The Motley Fool
January 14, 2010
Brian Orelli |
$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome. |
Chemistry World
November 21, 2013
Phillip Broadwith |
Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests. |
The Motley Fool
December 31, 2008
Brian Orelli |
Health Care's Golden Children The whole industry wasn't down this year. |
The Motley Fool
April 30, 2009
Brian Orelli |
How to Lose 75% of Your Company's Value Overnight Sequenom's shares sink 75% after the company said that four employees have been suspended because of "employee mishandling of R&D test data and results" for its revolutionary blood test for Down syndrome. |
The Motley Fool
July 22, 2009
Brian Orelli |
Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line. |
The Motley Fool
April 27, 2011
Brian Orelli |
Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby. |
The Motley Fool
July 24, 2008
Brian Orelli |
Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth. |
The Motley Fool
July 28, 2010
Brian Orelli |
Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense. |
The Motley Fool
July 25, 2007
Brian Orelli |
Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
